lating in the lungs in interstitial lung disease are neutrophils and macrophages. These cells secrete a large panel of cytokines and growth factors implicated in the injury and repair of the lungs. Transforming growth factor (TGF)-␤1 (29) , IL-1␤ (22) , TNF-␣ (28), platelet-derived growth factor (37) , granulocyte-macrophage colony-stimulating factor (36) , and connective tissue growth factor (6) have been shown to induce at least patchy areas of PF when overexpressed in normal mouse lungs, but there is evidence that other mediators are involved in this response.
One such factor, insulin-like growth factor I (IGF-I), is a pleiotropic cytokine related to insulin. The expression level of this cytokine is increased in the lungs of patients with PF (1, 5, 33) and fibroproliferative acute respiratory distress syndrome (ARDS) (23) . A role for IGF-I in fibroproliferation is supported by the fact that, in fibroblasts, IGF-I is highly mitogenic, is able to abrogate the spontaneous apoptotic response of these cells, and is able to induce collagen synthesis (8) . Furthermore, it was recently shown that abrogation of IGF-I receptor function improves outcome in a mouse model of bleomycin-induced lung fibrosis (9) . Nonetheless, overexpression of human IGF-IA (hIGF-IA) in a mouse model of bleomycin-induced lung injury failed to implicate hIGF-IA in the development of fibrosis (13) , raising questions about the involvement of IGF-I in this process.
The gene for IGF-I has been cloned and extensively characterized. It is expressed as a propeptide by the liver, macrophages, and a number of tissues and inflammatory cells (24) . In humans, three main isoforms of pro-IGF-I are produced by alternative splicing: IGF-IA, IGF-IB, and IGF-IC (2) . The major differences among these three precursors reside in their level of expression, intracellular localization, and composition of their "E peptide." All these isoforms are posttranslationally processed into an identical mature IGF-I peptide. A second level of complexity is reached by alternative use of transcription start sites located in exon 1 (class 1) and exon 2 (class 2). Class 1 IGF-IA is the most abundantly expressed isoform in healthy individuals. In PF patients, it was shown that the onset of fibrosis correlates with an increase in the class 1 IGF-IB isoform, as measured in cells recovered from bronchoalveolar lavage (BAL) fluid (BALF) (5) . Importantly, IGF-IB is the only isoform to localize to the nucleolus (32) . This particular intracellular localization could have biologically important consequences. Taken together, these data suggest a possible involvement of this isoform in the initiation and/or progression of PF.
To shed some light on the potential role of hIGF-IB in PF, we used adenoviral-mediated gene transfer technology to overexpress this isoform specifically in mouse lungs. We found that hIGF-IB transgene mRNA and IGF-I protein are expressed in alveolar macrophages as well as alveolar epithelial cells. hIGF-IB overexpression induced a strong inflammatory response, characterized by an increase in neutrophil, macrophage, and lymphocyte recruitment into the alveolar space, but no changes suggestive of fibrosis in the lung parenchyma and no concomitant change in the level of collagen deposition, despite in vitro data showing that hIGF-I is capable of inducing type III collagen-␣ 1 in human fetal lung (HFL-1) fibroblasts. We thus conclude that, in our noninjury mouse model, overexpression of hIGF-IB causes pulmonary inflammation but does not, by itself, induce PF.
MATERIALS AND METHODS
Recombinant adenovirus. The general principles and preparation of type 5 replication-deficient adenovirus have been described previously (3). Briefly, hIGF-IB cDNA was cloned into the pACCMV plasmid, which contains a human cytomegalovirus promoter and part of the type 5 adenovirus genome. Human embryonic kidney (HEK 293) cells were cotransfected with plasmids pACCMV and pJM17, which contains the rest of the type 5 adenovirus genome. After homologous recombination, replication-deficient type 5 adenovirus containing the hIGF-IB cDNA was generated, amplified, and purified by CsCl gradient ultracentrifugation. The integrity of the cloned hIGF-IB cDNA was confirmed by direct sequencing. The adenoviralmediated expression of hIGF-IB mRNA and protein was assessed in transfected HEK 293 cells and confirmed by RT-PCR and Western blotting. Empty adenovirus was generated in the same way, except no foreign gene was inserted into the adenovirus genome. This AdEmpty vector was used in the control group.
Animal treatment. Male C57BL/6 mice (5-7 wk old; Charles River Laboratories, St. Constant, QC, Canada) were treated according to the Canadian Council of Animal Care guidelines; ethical approval for this study was obtained from our Institutional Review Board. A schematic of the experimental plan is shown in Fig. 1 . Mice were anesthetized by inhalation of isoflurane, and 2.5 ϫ 10 10 optical particle units of AdIGF-I virus in 50 l of sterile PBS were intratracheally injected into the lungs. Briefly, anesthetized mice were hung by their front teeth on a horizontal suture. A 0.5-cm midline incision was made in the neck for visualization of the trachea. Then a 24-gauge gavage needle was carefully inserted into the trachea through the mouth, with the trachea used as a visual guide. Virus solution (50 l) was injected into the trachea via a 1-ml syringe attached to the gavage needle. Distribution of adenovirus solution into the lungs was facilitated by vertical suspension of the mice, until they began to awaken. Control mice were injected in the same way with 50 l of AdEmpty virus at the same optical particle unit level. At 3, 7, 14, 21 , and 42 days after adenovirus exposure, eight control (AdEmpty virus) mice and eight AdIGF-I-treated mice were killed by cervical dislocation, and samples were collected as described below.
Four mice in each group were subjected to BAL. Briefly, a 23-gauge 3/4-in. needle with a cannula at the end was inserted into the trachea and tied with a suture. Then 1 ml of sterile 4°C PBS in a 1-ml syringe attached to the needle was slowly injected into the lungs and retrieved; this injection-and-retrieval process was repeated three more times with 0.8 ml of PBS. The last three aliquots of retrieved BALF were pooled and kept separate from the first aliquot. All the BALF samples were centrifuged at 400 g, 4°C for 10 min. The supernatants were stored separately at Ϫ80°C for further analysis. The cell pellets were resuspended and pooled into 1 ml of PBS for total and differential cell counts. After the BAL, the whole lung was extracted, snap-frozen in liquid nitrogen, and stored at Ϫ80°C for hydroxyproline assay. For the other four mice in each group, the left lung was cut off, snap-frozen in liquid nitrogen, and stored at Ϫ80°C for mRNA study. The right lung was extracted and then inflated with 10% neutral buffered formalin for 20 min using a 30-cm-high formalin column to ensure equal inflation pressure. Then the inflated right lung was immersed in 10% neutral buffered formalin overnight for further processing and histological evaluation.
Measurement of IGF-I mRNA expression in lung tissue. hIGF-IB transgene mRNA expression in lung tissue was detected by RT-PCR (SuperScript One-Step RT-PCR kit, Invitrogen, Burlington, ON, Canada). hIGF-IB-specific primer pair [ATTGCTCTCAACATCTC-CCATC (forward) and TTCCGTTTTCTCCATGTTTCTT (reverse)] was designed according to the known published sequence (27) . For each reaction, 0.5 g of total lung RNA treated with DNase using a DNA-free kit (Ambion, Austin, TX) was used. Reverse transcription consisted of 30 min of incubation at 50°C followed by 35 PCR cycles. Mouse GAPDH primer pair [CAACTTTGGCATCGTGGAAGG (forward) and CAACGGATACATTGGGGGTAG (reverse)] was used in a separate reaction as an internal control. The PCR products were resolved on a 1% agarose gel that was subsequently stained with ethidium bromide, visualized using a transilluminator, and imaged using a Kodak camera system. The images were then scanned and digitized.
Measurement of hIGF-I and mouse TGF-␤1 protein levels in BALF. The supernatant of the first 1-ml aliquot of BALF was used for these assays. The supernatant (500 l) was concentrated by centrifugation through a Microcon YM-3 filter (Millipore, Bedford, MA) at 10,000 rpm for 100 min at room temperature. Concentrated BAL samples were assayed in duplicate for hIGF-I protein using a Quantikine hIGF-I Immunoassay kit (R & D Systems, Minneapolis, MN) and for endogenous TGF-␤1 protein using a Quantikine Human TGF-␤1 Immunoassay kit (R & D Systems), which cross-reacts with mouse TGF-␤1.
Total and differential cell counts in BALF. Ten microliters of the BALF cell suspension were mixed with 80 l of PBS and 10 l of Turk Blood-Diluting Fluid (Ricca Chemical, Arlington, TX). The mixture (10 l) was loaded onto a hemocytometer, and total cell numbers were determined. Results are reported as total number of cells per milliliter of BALF. A Cytospin (550 rpm for 5 min) was used to spin 50,000 cells in 500 l of PBS onto slides. Cells were fixed in methanol for 1 min and then stained with eosin for 45 s and hematoxylin for 15 s. Differential cell count was performed by random field count of a total of 200 cells. Results are reported as population percentages for different cell types.
Histology and immunohistochemistry. Formalin-fixed lung tissue was cut latitudinally into 2-mm-thick pieces, one piece from each lobe of the three lobes in the right lung. The lung pieces were dehydrated Fig. 1 . Experimental plan. At each time point, 8 mice were treated with AdIGF-1B or AdEmpty, then they were divided into 2 groups: mice 1-4 were subjected to bronchoalveolar lavage (BAL), then the lungs were taken for hydroxyproline assay. Right lungs of mice 5-8 were collected for mRNA extraction, and left lungs were used for histological studies. IGF-I, insulin-like growth factor I. in 50%, 75%, 90%, and 95% ethanol and then three times in 100% ethanol sequentially (1 h for each concentration), embedded in paraffin, and then cut into 4-m-thick sections. The sections were deparaffinized in xylene, washed twice in 100% ethanol and once in 95% ethanol, and finally brought into water. Standard hematoxylinand-eosin staining was then performed. After staining, the slides were soaked once in 95% ethanol, twice in 100% ethanol, and once in xylene before they were mounted with Permount.
For IGF-I immunohistochemistry, antigen retrieval was performed on deparaffinized and hydrated lung sections, which were boiled in citric acid (pH 6.0) for 30 min and then cooled at room temperature for 30 min. Sections were then treated with 3% H 2O2 for 30 min to block endogenous peroxidase. A Mouse-on-Mouse Immunodetection kit (Vector Laboratories, Burlingame, CA) was used to eliminate the cross-reaction with endogenous mouse antibody. Sections were incubated in mouse monoclonal anti-IGF-I antibody (1:100 dilution; Upstate, Charlottesville, VA) for 3 h at room temperature. Sections that were not treated with primary antibody served as control for nonspecific staining. The staining was finally visualized using an avidin-biotin-based Vectastain detection kit (Vector Laboratories).
Hydroxyproline assay of collagen content in lungs. The mouse lungs were desiccated in a lyophilizer at Ϫ20°C for 48 h, and 15 mg of desiccated lung tissue were ground and hydrolyzed with 6 N HCl at 115°C overnight. Hydrolyzed samples were assayed for hydroxyproline content, as previously described (13) . All samples and hydroxyproline standards (Sigma, Oakville, ON, Canada) were measured in duplicate in three to four animals at each time point. Collagen content is presented as micrograms of collagen per milligram of desiccated lung tissue.
Sirius red staining and image analysis. Collagen deposition in the lungs was visualized by Sirius (picro-Sirius) red staining, as previously described (20) . Briefly, lung sections were deparaffinized and hydrated as described above. Sections were then immersed in Sirius red solution (0.1% Sirius red in saturated picric acid, pH 2.0) for 1 h, rinsed briefly in 0.01 N HCl solution and then for 1 min in water, counterstained with Mayer's hematoxylin for 1 min, and washed with warm tap water for 1 min. Sections were dehydrated, cleared, and mounted as described above. Sirius red-stained lung sections were observed under a polarized-light Zeiss Axioplan microscope with a ϫ10 objective for visualization of collagen deposition (20) . Several microscopic images of random areas of each lung section with and without polarized light were obtained using a Nikon Coolpix 995 digital camera that was mounted on the microscope. The camera was set with infinite focus, auto aperture, and maximum zoom; 1/250 s camera shutter speed was used for nonpolarized images, and 1/15 s camera shutter speed was used for polarized images. Images were analyzed using Image J software as follows. Images of lung parenchyma devoid of large airways and large vessels were photographed (10 images per lung section) under polarized light. The image was inverted so that collagen appeared as dark areas, and the dark pixels were quantified per 100 m 2 by two blinded individuals using Image J software.
Measurement of in vitro type I and III collagen-␣1 expression in fibroblasts.
The HFL-1 cell line was obtained from American Type Culture Collection (Manassas, VA) and cultured in DMEM, 10% FBS, and a mixture of penicillin (100 U/ml), streptomycin (100 g/ml), and L-glutamine (PSG, 2 mmol/l; Invitrogen). Recombinant hIGF-I and porcine TGF-␤ were obtained from R & D Systems and reconstituted according to the manufacturer's instructions.
Cells were plated at a density of 0.2 ϫ 10 6 cells per well in 24-well plates, immediately transferred to a low-serum-containing medium (DMEM ϩ 0.5% FBS ϩ PSG), and maintained in this medium for the duration of the experiment. At 24 h after they were plated, the cells were treated with 5 ng/ml of TGF-␤ or 50 ng/ml of hIGF-1 for 24 h and then rinsed once with PBS at 37°C, and total RNA was extracted using a Purelink RNA Micro kit (Invitrogen) according to the manufacturer's instructions. Total RNA was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Nepean, ON, Canada). cDNA was generated from 0.5 g of total RNA using the RT2 First-Strand kit (catalog no. C-03, SABiosciences, Frederick, MD) according to the manufacturer's instructions. Real-time quantitative PCR was performed using the following Taqman gene expression assays (Applied Biosystems, Foster City, CA): COL1A1 Hs00164004_m1 for type I collagen, COL3A1 Hs00164103_m1 for type III collagen, and the reference gene eukaryotic 18S rRNA (catalog no. 4314913E). Samples were run on a 7900HT Fast real-time PCR system (Applied Biosystems), and the cycling parameters were set as follows: 50°C for 2 min, 95°C for 10 min, and 40 cycles at 95°C for 15 s and 60°C for 1 min. The data were analyzed using RQ Manager (version 1.2) software.
Statistical analysis. Values are means Ϯ SE. STATA 8.0 software was used for all statistical analysis. ANOVA was used to compare the results of all five time points of control or treatment groups. A two-tailed t-test was used to compare the results of control and treatment groups at any one time point, with Bonferroni's post hoc correction. Difference was considered statistically significant at P Ͻ 0.05.
RESULTS

hIGF-IB transgene is expressed in mouse lungs.
To study the role of hIGF-IB in pulmonary fibroproliferation, we chose a model of adenovirus-mediated gene transfer of hIGF-IB into the lungs of C57BL/6 mice. This model was chosen because adenovirus vectors can transduce lung epithelial and interstitial cells in the lung parenchyma (15) . This ensures the interaction of hIGF-IB with alveolar and mesenchymal cells and, thus, can more accurately reveal the activities of hIGF-I in PF.
For verification that the hIGF-IB transgene was expressed in this model, RT-PCR was performed on total RNA extracted from transduced mouse lungs. As shown in Fig. 2 , hIGF-IB mRNA is clearly detectable in the AdIGF-IB-transduced mice at all five time points, except for two mice (1 at day 14 and 1 at day 21, as shown in the representative RT-PCR), which were excluded from subsequent studies. Figure 3 demonstrates that hIGF-I protein was successfully expressed and detected as early as posttransduction day 3 in BALF of the AdIGF-IB-transduced mice but returned to basal levels by day 21. This pattern of expression after adenovirusmediated transgene delivery is consistent with previous studies (34) and is specific, since we were unable to detect elevated hIGF-IB mRNA (Fig. 2) or protein (Fig. 3) in the AdEmptytransduced control mouse lungs.
Immunohistochemistry was performed on sections of mouse lungs to determine which cell types express the transgene. As shown in Fig. 4 , hIGF-IB gene product is detected in alveolar macrophages and alveolar epithelial cells by posttransduction days 3 and 7. These results show that multiple cell types were able to express the transgene and that the pattern of expression of the hIGF-IB transgene closely mimics the distribution of IGF-I in biopsies of patients with early-stage PF (18) and in fibroproliferative ARDS (23) . Control slides without primary antibody treatment showed no background staining (data not shown).
Inflammatory cell recruitment is detectable in BALF of hIGF-IB transduced mice. Lung damage is believed to be caused, at least in part, by inflammatory mediators secreted by infiltrating neutrophils and monocytes/macrophages. However, for most causes of PF, the signals for the recruitment and infiltration of these inflammatory cells into the lung are not known. To determine whether hIGF-IB can act as a recruitment signal for these inflammatory cells, total cell counts were performed on the BAL of the AdEmpty-and AdIGF-IBtransduced mice on days 3, 7 14, 21, and 42. As shown in Table 1 , the total cell count was twofold higher in lungs of AdIGF-IB-than AdEmpty-transduced mice. This increase was observed as early as day 3, peaked on day 14, and was sustained until day 42. This result suggests that hIGF-IB transgene expression induced significant cell recruitment (inflammation) into the alveolar spaces.
To determine which cell types are recruited to the lungs by hIGF-IB, a differential cell count was performed on the cell population recovered in BALF from AdIGF-IB-transduced mice. Three major cell types were recovered: macrophages, neutrophils, and lymphocytes. The differential counts in AdEmpty-and AdIGF-I-transduced mice are shown in Table 1 . We observed a difference not only in the total number of cells recruited, but also in the kinetics of the recruitment of these inflammatory cells. AdIGF-I-transduced mice exhibited a large influx of neutrophils as early as day 3 that quickly subsided and was completely resolved by day 21. This neutrophil influx was not seen in control mice, suggesting that the overexpression of hIGF-IB, not the adenoviral vector itself, is responsible for this acute inflammatory response. The number of macrophages in BALF from AdIGF-IB-transduced mice was significantly increased compared with that from AdEmpty-transduced mice only at day 42. This sequential recruitment of inflammatory cells is consistent with a role of neutrophils in the recruitment of macrophages. A steady increase in lymphocyte counts was also seen in the AdIGF-IB-transduced mice during the first 2 wk after transduction, reaching a plateau at day 21 and decreasing by day 42. In comparison, control mice showed only a minimal lymphocytic infiltration, which may be caused by the adenovirus itself.
Lung histology reveals that hIGF-IB transgene expression induces inflammatory cell accumulation. As evident on the representative hematoxylin-and-eosin-stained sections in Fig. 5 , a small amount of inflammatory cell accumulation occurs around the peribronchial area in the AdIGF-IB-transduced mice as early as posttransduction day 3, with no apparent change in the parenchymal area. By day 7, significant inflammatory cell influx was seen in the peribronchial, perivascular, and parenchymal areas of the AdIGF-IB-transduced mouse lungs. The inflammatory cell influx around the peribronchial and perivascular areas persisted but largely resolved in the parenchymal area by day 42. In control mice, a mild inflammation induced by the AdEmpty virus was observed in the peribronchial area at days 3 and 7 and resolved by day 21. Thus the adenovirus itself causes a minimal, self-limited inflammatory process in the lungs of AdEmpty-transduced mice.
hIGF-IB transgene expression does not cause collagen deposition in the lung. Collagen is the most common form of extracellular matrix protein recovered in fibrotic lung tissue. Therefore, to determine whether AdIGF-IB is able to induce a fibrotic response in transduced lungs, we used a hydroxyproline assay to measure the amount of collagen in the lungs of the transduced mice. As shown in Fig. 6 , at no time did collagen content differ between AdEmpty-and AdIGF-I-transduced mice, suggesting that expression of hIGF-IB alone does not result in an increase in collagen deposition in this noninjury mouse model. Because collagen deposition is better visualized using Sirius red stain than by hydroxyproline assay, we stained the lung section with Sirius red (Fig. 7) . In AdEmpty-and AdIGF-IB-transduced mouse lung sections, Sirius red staining showed collagen deposition only in the peribronchial and perivascular areas, which represent the connective tissue normally found around the bronchi and blood vessels, but no significant collagen deposition in the parenchyma (data not shown). Since PF is characterized by large amounts of collagen deposition, specifically in the lung parenchyma, these results suggest that hIGF-IB overexpression alone in otherwise normal (noninjured) mouse lungs does not induce collagen deposition (PF).
BALF of AdIGF-IB-transduced mice is unable to stimulate transcription of type I and/or III collagen-␣ 1 in vitro in human
fibroblasts. The lack of collagen accumulation in vivo could be caused by an inability of hIGF-IB to induce collagen expression or by an increase in collagen degradation. To differentiate these two options, we incubated human fibroblasts with the mouse BAL recovered 3 days after AdIGF-IB transduction. As shown in Table 2 , hIGF-IB in the BALF does not induce transcription of type I or III collagen-␣ 1 , as measured by real-time quantitative PCR. This lack of induction was not due to this cell line, since we show that HFL-1 cells were indeed able to induce expression of types I and III collagen-␣ 1 , in response to TGF-␤ alone (5 ng/ml), by 2.3-and 1.7-fold, respectively (P Ͻ 0.01, 1-way ANOVA, Dunnett's multiple comparisons). At a concentration similar to that recovered in BALF, i.e., 0.5 ng/ml, hIGF-I was unable to induce type I or III collagen-␣ 1 in HFL-1 cells (data not shown); 5 and 10 ng/ml of purified hIGF-I also failed to induce a transcriptional response. The possibility remained that hIGF-I measured in our BALF was too dilute to have a biological effect but that its local concentration, in the lung alveoli, was much higher and could have a biological effect. Therefore, we incubated human fibroblast cells with 50 ng/ml of purified hIGF-I, a concentration 100 times higher than that recovered in the BALF of the AdIGF-IB-expressing mouse on posttransduction day 3. As previously reported (6) , at this high concentration (50 ng/ml), we were able to demonstrate the ability of IGF-I to induce the transcription of type III, but not type I, collagen-␣ 1 in HFL-1 cells. 5 total cells) are means Ϯ SE (n ϭ 3-4 in each group). BAL, bronchoalveolar lavage; IGF-I, insulin-like growth factor I; UD, undetectable. *P Ͻ 0.05 vs. control.
DISCUSSION
We questioned whether hIGF-IB expression alone could induce PF in mouse lungs. To answer this question, we delivered an adenovirus vector containing hIGF-IB into the lungs of mice. Using RT-PCR, we were able to confirm that the transgene was expressed in the lungs of the transduced mice. We also confirmed that the class 1 hIGF-IB isoform is expressed in alveolar epithelial cells and alveolar macrophages. This pattern of expression is closely correlated with previous observations in patients with early-stage PF (18, 33) and patients with fibroproliferative ARDS (23) . The amount of hIGF-I protein secreted in the alveolar space was measured in BALF by ELISA. We determined that the expression reached a maximum by posttransduction day 3 and returned to basal levels by day 21. The number and type of cells in BALF of AdIGF-IBand AdEmpty-transduced mice were examined up to day 42. The number of cells in the BALF of AdIGF-I-transduced mice was increased, and the differential cell count revealed that hIGF-IB was able to mediate the recruitment of inflammatory cells (neutrophils, macrophages, and lymphocytes) into the lungs, compared with the AdEmpty-transduced controls. We determined that the expression of hIGF-IB was unable to induce collagen deposition in the lungs of AdIGF-IB-transduced mice. Furthermore, on posttransduction day 3, BALF from AdIGF-IB-transduced mice was incapable of inducing collagen expression in vitro in human fibroblasts, confirming our in vivo findings, although hIGF-I (50 ng/ml) induced type III collagen-␣ 1 in HFL-1 cells in vitro. On day 3, BALF isolated from AdEmpty-transduced control mice also did not On days 3, 7, 14, 21 , and 42, lungs were collected for measurement of collagen content by hydroxyproline assay.
induce collagen in fibroblasts in vivo or in vitro. The results of these experiments reveal that hIGF-IB expression in mouse lungs is unable, on its own, to induce fibroblast proliferation or collagen deposition in AdIGF-IB-transduced mouse lungs.
PF is believed to be a consequence of the dysregulation of the three phases of tissue repair: injury, inflammation, and repair (35) . By directly or indirectly regulating these processes, cytokines and growth factors play an essential role in the accumulation of collagen and the progression of fibrosis in the lungs. IGF-I is a cytokine that has been consistently detected in the lungs of patients with PF (1, 5, 18, 33) and late ARDS (23) . Nonetheless, it is unknown whether IGF-I is involved in the initiation and/or progression of PF. Data presented here strongly suggest that IGF-IB is not involved in initiating fibrosis on its own.
The mature form of IGF-I is produced by posttranslational processing of one of two classes of transcripts, each divided into three pro-IGF-I isoforms obtained by alternative splicing. Exons 5 and 6 do not participate in the mature form of IGF-I. Instead, it has been shown that they encode one or two biologically active peptides, depending on the isoform. For example, hIGF-IB encodes two E peptides, IBE1 and IBE2, and IBE1 has been shown to possess growth-promoting ability independently of IGF-I (4). The abundance of each isoform is tissue-and stimulus-dependent. For example, in normal cells, the most abundantly and ubiquitously expressed pro-IGF-I isoform is the class 1 IGF-IA. In contrast, IGF-IC, also referred to as mechano growth factor, is mainly expressed in striated muscle cells (2) . Given the low abundance of this type of cell in the pulmonary alveoli, we believe that IGF-IC is unlikely to Fig. 7 Values are means Ϯ SE (n ϭ 5-10 experiments per group). Human fibroblasts (HFL-1 cells) were exposed to purified human IGF-I (50 ng/ml), purified transforming growth factor-␤ (TGF-␤, 5 ng/ml), or BAL fluid from AdEmpty-or AdIGF-IB-transduced mice (day 3, 1:16 dilution). After 24 h of incubation, total mRNA was extracted, and relative expression of type I and III collagen-␣1 was assessed by real-time quantitative PCR. *P Ͻ 0.05 vs. control. significantly contribute to PF. On the other hand, class 1 IGF-IB propeptide is the predominant isoform recovered in the BAL cells of fibrotic patients, as demonstrated by Bloor and colleagues (5) . Our results show that expression of class 1 hIGF-IB in lungs of normal mice induces a significant and sustained infiltration of inflammatory cells into the lungs. Interestingly, in our mouse model, hIGF-I expression in the BALF is approximately three times higher than hIGF-IA expression in the mouse model of Frankel et al. (13) . These results suggest that the hIGF-IB propeptide could have the capacity to induce an inflammatory response in the lung. By localizing to the nucleolus (32), this isoform may be able to control the transcription of genes important for initiation of the inflammatory response or propagation of the repair process.
It has been suggested that cytokines that induce the production of TGF-␤1, such as IL-1␤, are necessary to initiate the fibroproliferative process in PF (14) . In sharp contrast, TGF-␤1 was not induced by hIGF-IB expression in the mouse lungs (data not shown), possibly explaining the lack of initiation of the fibroproliferative response in our model.
We show here that AdIGF-IB does induce an inflammatory infiltrate in the lungs compared with AdEmpty-transduced mouse lungs. IGF-I has been shown to promote migration (chemotaxis) of bone marrow-derived human mesenchymal progenitor cells (12) , human T cells through thymic epithelial cells (11) , murine bone marrow stem cells (21) , vascular smooth muscle cells (26) , and breast cancer cells (10) , as well as other inflammatory cells. The potential role of IGF-I in chemotaxis may be significant, because it is believed that the infiltrating inflammatory cells can promote repair of the lung tissues by inducing cellular proliferation and collagen deposition, the dysregulation of which may lead to PF. Myofibroblasts and fibroblasts are the two main cell types responsible for the deposition of collagen at the site of tissue damage. In vitro studies have shown that IGF-I can be a potent inducer of collagen expression and cellular proliferation (7, 30, 31) . Indeed, in vitro studies by Harrison et al. (17) clearly demonstrated a role for IGF-I in fibroblast proliferation in patients with systemic sclerosis. In addition, Goldstein et al. (16) showed that IGF-I induces collagen deposition in human embryonic lung fibroblast cultures. Our results do not correlate with these observations, since we did not observe an increase in collagen deposition or fibroproliferation in the lungs of mice injected with an hIGF-IB-expressing vector. In fact, fibroblasts were not activated to induce ␣-smooth muscle actin (data not shown) or collagen, at any time point tested, in AdIGF-IBcompared with AdEmpty-transduced mice.
However, in PF, collagen accumulation is dependent on the balance between collagen production and degradation. It is therefore possible that even if hIGF-IB is able to promote the collagen deposition, no collagen accumulation would be detected in vivo because of the activity of the collagenase enzymes. Indeed, Choi and colleagues (9) used a monoclonal blocking antibody against the IGF-I receptor to study the role of IGF-I in lung fibrosis. They showed that IGF-I does not play a role in the initial establishment of fibrosis, but they hypothesized that it may be involved in the perpetuation of the fibrotic signal. Furthermore, overexpression of class 1 hIGF-IA in a mouse model (13) was also unable to induce PF. These results are in agreement with our findings, since we show that expression of class 1 hIGF-IB in vivo, on its own, is unable to induce collagen deposition in mouse lungs.
Damage to alveolar epithelial cells often results in apoptosis of these cells. IGF-I has been shown to inhibit apoptosis of epithelial cells as well as mesenchymal cells. These antiapoptotic effects may have profibrotic and antifibrotic activities. Inhibition of epithelial cell apoptosis has an antifibrotic effect, because it inhibits loss of the epithelium, whereas inhibition of mesenchymal cell (fibroblast) apoptosis may be profibrotic, since the persistence of these cells may yield more matrix production.
This leads us to hypothesize that class 1 hIGF-IB alone is insufficient to induce PF or more than one class 1 isoform needs to be expressed to induce this response. The biological activity of IGF-I is regulated at many different levels, and alternative splicing is only one of them. It was shown that IGF-binding proteins (IGFBP) mediate a different level of control by modulating the access of IGF-I to its receptor. The expression pattern of members of the IGFBP family is highly variable: IGFBP-3 is the most abundant in plasma, and IGFBP-5 is the most highly conserved (19) . The expression level of both of these proteins has been shown to be upregulated in idiopathic PF lung tissues, in conjunction with IGF-I (25). Therefore, it is possible that expression of IGF-I alone is insufficient to induce fibrosis because of the limited amount of available IGFBP-3 and/or -5. In addition, one must seriously consider the role that IGF-I may play in the apoptosis of fibroblasts: if IGF-I delays activated fibroblast apoptosis, it would allow for more accumulation of matrix and increased fibrosis. However, our studies did not focus on this alternative, since collagen deposition itself was not initiated by AdIGF-IB expression alone, nor was collagen induced in IGF-I-spiked BALF at physiological doses when cultured with a fibroblast (HFL-1) cell line. The IGF-I concentration achieved in this AdIGF-IB mouse model (0.5 ng/ml at posttransduction day 3) is significant, because the level of IGF-I produced in epithelial lining fluid in humans with fibroproliferative ARDS is 0.5-14 ng/ml (unpublished observations). Thus our AdIGF-IB mouse model produces a level of IGF-I in BALF of the same order of magnitude as in human epithelial lining fluid, where pulmonary fibroproliferation is occurring. In our in vitro studies, only at a high dose of IGF-1 (50 ng/ml) were we able to detect type III collagen-␣ 1 mRNA induction in HFL-1 cells. Therefore, in vivo and in vitro, physiological concentrations of IGF-I (0.5 ng/ml) were unable to induce significant collagen production.
In conclusion, we found that the sole expression of class 1 hIGF-IB in mouse lungs is not sufficient to induce PF in an otherwise normal or uninjured mouse model. Given the complexity of the control of the tissue repair process, it is conceivable that IGF-I needs to be expressed concomitantly or sequentially with other profibrotic agents, such as IL-13 and/or TGF-␤, to tip the delicate repair process toward fibrosis.
